TEVA PHARMACEUTICAL INDUSTRIES LTD
For the period ended Jun 30, 2025. Filed Jul 30, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Jul 30, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Legal Proceedings
| ITEM 1. | LEGAL PROCEEDINGS |
|---|
We are subject to various litigation and other legal proceedings. For a discussion on our Commitments and Contingencies see note 10 to our consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form
10-Q.
In addition, on January 15, 2025, Teva filed a complaint against CMS and HHS in the U.S. District Court for the District of Columbia, challenging the processes and guidance that the U.S. Government is using to implement the Inflation Reduction Act (the IRA), seeking injunctive relief against implementation of the Drug Price Negotiation Program. The lawsuit alleges that CMS’s implementation of the Drug Price Negotiation Program portion of the IRA is arbitrary and contrary to the plain meaning of the statute, in violation of the Administrative Procedure Act (“APA”), and is therefore unconstitutional.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.